Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 5:27 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 265–288 of 12,508 matching trials from the live ClinicalTrials.gov search.
Filters: Miami, Florida Clear all
Active, not recruiting No phase listed Observational

NCI COVID-19 in Cancer Patients, NCCAPS Study

NCT04387656
View directory record Official record
Conditions
COVID-19 Infection, Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm
Interventions
Biospecimen Collection, Data Collection, Quality-of-Life Assessment, Questionnaire Administration
Procedure · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
1,877 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
928
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 589 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2026 · Synced Oct 31, 2026, 5:27 AM EDT
Terminated Phase 3 Interventional Results available

Open-Label Safety and Tolerability of Oxymorphone IR and ER in Opioid Tolerant Pediatric Subjects

NCT00765856
View directory record Official record
Conditions
Chronic Pain
Interventions
Oxymorphone ER
Drug
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
6 Years to 17 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
13
States / cities
Little Rock, Arkansas • Stanford, California • Aurora, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2020 · Synced Oct 31, 2026, 5:27 AM EDT
Enrolling by invitation Not applicable Interventional

Addressing Psychosocial Comorbidities in HIV Treatment and Prevention 2b

NCT05352061
View directory record Official record
Conditions
Medication Adherence, Mental Health Issue
Interventions
CBT for Syndemics and Adherence Factors
Behavioral
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 26, 2026 · Synced Oct 31, 2026, 5:27 AM EDT
Completed Phase 2 Interventional Results available

S0601 Rituximab, Combination Chemotherapy, and Bortezomib Followed by Bortezomib Alone in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma

NCT00376961
View directory record Official record
Conditions
Lymphoma
Interventions
rituximab, bortezomib, cyclophosphamide, doxorubicin hydrochloride, prednisone, vincristine sulfate
Biological · Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years to 120 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2017
U.S. locations
147
States / cities
Anchorage, Alaska • Tucson, Arizona • Little Rock, Arkansas + 95 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2017 · Synced Oct 31, 2026, 5:27 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Dose Finding Study In Subjects With Crow's Feet

NCT01951742
View directory record Official record
Conditions
Lateral Canthal Lines, Crow's Feet
Interventions
ANT-1401, Vehicle
Biological
Lead sponsor
Anterios Inc.
Industry
Eligibility
30 Years to 60 Years
Enrollment
145 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
10
States / cities
Miami, Florida • Pinellas Park, Florida • West Palm Beach, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated May 29, 2014 · Synced Oct 31, 2026, 5:27 AM EDT
Completed Phase 3 Interventional Results available

A Study of Factor XIII Concentrate in Subjects With Congenital Factor XIII Deficiency

NCT00885742
View directory record Official record
Conditions
Factor XIII Deficiency
Interventions
FXIII Concentrate (Human)
Biological
Lead sponsor
CSL Behring
Industry
Eligibility
Not listed
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
22
States / cities
Dothan, Alabama • Oakland, California • Orange, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2012 · Synced Oct 31, 2026, 5:27 AM EDT
Completed Not applicable Interventional Results available

HEMOBLAST Pivotal Clinical Investigation

NCT02780869
View directory record Official record
Conditions
Hemostasis
Interventions
HEMOBLAST Bellows, Absorbable gelatin sponge, USP with thrombin
Device
Lead sponsor
Biom'Up France SAS
Industry
Eligibility
21 Years and older
Enrollment
258 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
17
States / cities
Phoenix, Arizona • Los Angeles, California • Pasadena, California + 12 more
Source: ClinicalTrials.gov public record
Updated Dec 27, 2018 · Synced Oct 31, 2026, 5:27 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Switching From Regimens of ABC/3TC + a 3rd Agent to E/C/F/TAF Fixed-Dose Combination (FDC) in Virologically-Suppressed HIV 1 Infected Adults

NCT02605954
View directory record Official record
Conditions
HIV-1 Infection
Interventions
E/C/F/TAF, ABC/3TC, Third Antiretroviral Agent
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
275 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
12
States / cities
Phoenix, Arizona • Los Angeles, California • Washington D.C., District of Columbia + 8 more
Source: ClinicalTrials.gov public record
Updated Nov 14, 2018 · Synced Oct 31, 2026, 5:27 AM EDT
Active, not recruiting Phase 3 Interventional

Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque Psoriasis

NCT06846541
View directory record Official record
Conditions
Plaque Psoriasis, Psoriasis (PsO), Psoriasis, Moderate Psoriasis, Severe Psoriasis
Interventions
Open-Label Envudeucitinib, Blinded Envudeucitinib, Placebo
Drug
Lead sponsor
Alumis Inc
Industry
Eligibility
18 Years and older
Enrollment
1,680 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
92
States / cities
Birmingham, Alabama • Chandler, Arizona • Pheonix, Arizona + 79 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 31, 2026, 5:27 AM EDT
Completed Phase 3 Interventional

Satraplatin in Hormone Refractory Prostate Cancer Patients Previously Treated With One Cytotoxic Chemotherapy Regimen

NCT00069745
View directory record Official record
Conditions
Prostate Cancer, Hormone Refractory Prostate Cancer
Interventions
Satraplatin, Prednisone
Drug
Lead sponsor
Agennix
Industry
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
105
States / cities
Birmingham, Alabama • Phoenix, Arizona • Sedona, Arizona + 90 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2012 · Synced Oct 31, 2026, 5:27 AM EDT
Completed Phase 3 Interventional Results available

Safety of Twice Daily Oxycodone Hydrochloride Controlled-release Tablets in Children With Moderate to Severe Malignant and/ or Nonmalignant Pain Requiring Opioids

NCT01192295
View directory record Official record
Conditions
Pain
Interventions
Oxycodone HCl controlled-release tablets
Drug
Lead sponsor
Purdue Pharma LP
Industry
Eligibility
6 Years to 16 Years
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
35
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 31 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2020 · Synced Oct 31, 2026, 5:27 AM EDT
Completed Phase 3 Interventional Results available

Study HZA106829: Efficacy/Safety Study of Fluticasone Furoate/Vilanterol (GW642444) in Adult and Adolescent Asthmatics

NCT01134042
View directory record Official record
Conditions
Asthma
Interventions
Fluticasone Furoate/Vilanterol Inhalation Powder, Fluticasone Furoate Inhalation Powder, Fluticasone Propionate Inhalation Powder, Placebo Inhalation Powder 1, Placebo Inhalation Powder 2
Drug · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years and older
Enrollment
587 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
23
States / cities
Bell Gardens, California • Huntington Beach, California • Long Beach, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2017 · Synced Oct 31, 2026, 5:27 AM EDT
Completed Phase 2 Interventional Results available

Efficacy, Safety, and Tolerability of Selonsertib (GS-4997) in Participants With Diabetic Kidney Disease

NCT02177786
View directory record Official record
Conditions
Diabetic Kidney Disease
Interventions
Selonsertib, Placebo to match selonsertib
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
334 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
100
States / cities
Birmingham, Alabama • Huntsville, Alabama • Toney, Alabama + 81 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2019 · Synced Oct 31, 2026, 5:27 AM EDT
Completed Phase 3 Interventional Results available

Idalopirdine in Patients With Mild-moderate Alzheimer's Disease Treated With Donepezil

NCT02006641
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Placebo, Idalopirdine
Drug
Lead sponsor
H. Lundbeck A/S
Industry
Eligibility
50 Years and older
Enrollment
858 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
48
States / cities
Phoenix, Arizona • Fayetteville, Arkansas • Anaheim, California + 43 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2018 · Synced Oct 31, 2026, 5:27 AM EDT
Completed Phase 3 Interventional

A Study To Evaluate The Efficacy And Safety Of A Once-Daily Investigational Nasal Spray In Adults And Adolescents With Perennial Allergic Rhinitis (PAR).

NCT00103454
View directory record Official record
Conditions
Rhinitis, Allergic, Perennial
Interventions
GW685698X
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years and older
Enrollment
288 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005
U.S. locations
43
States / cities
Little Rock, Arkansas • Los Angeles, California • Mission Viejo, California + 37 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2016 · Synced Oct 31, 2026, 5:27 AM EDT
Completed Not applicable Interventional

Cognitive Behavioral Stress Management (CBSM) & Prostate Cancer

NCT05486754
View directory record Official record
Conditions
Stress
Interventions
Cognitive behavioral stress management, Psychoeducational Control
Behavioral
Lead sponsor
University of Miami
Other
Eligibility
50 Years and older · Male only
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2006
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 4, 2022 · Synced Oct 31, 2026, 5:27 AM EDT
Recruiting Not applicable Interventional

Use of CereGate Therapy for Freezing of Gait in PD

NCT05292794
View directory record Official record
Conditions
Parkinson Disease, Freezing of Gait, Deep Brain Stimulation
Interventions
CereGate Software; BSN cDBS Programmer; BSN Burst Programmer
Device
Lead sponsor
CereGate Inc.
Industry
Eligibility
21 Years to 80 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
7
States / cities
Redwood City, California • Aurora, Colorado • Miami, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Oct 31, 2026, 5:27 AM EDT
Completed Not applicable Interventional

Chyme Reinfusion for Type 2 Intestinal Failure

NCT04577456
View directory record Official record
Conditions
Intestinal Failure, Enterocutaneous Fistula, Ileostomy - Stoma, High Output Stoma
Interventions
The Insides System
Device
Lead sponsor
The Insides Company
Industry
Eligibility
21 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
4
States / cities
Gainesville, Florida • Miami, Florida • Chicago, Illinois + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 8, 2025 · Synced Oct 31, 2026, 5:27 AM EDT
Completed Phase 3 Interventional Results available

A Study (Study 1) to Evaluate the Safety and Efficacy of FMX103 1.5% Topical Minocycline Foam in the Treatment of Facial Papulopustular Rosacea

NCT03142451
View directory record Official record
Conditions
Facial Papulopustular Rosacea
Interventions
FMX103 minocycline foam 1.5%, Vehicle foam
Drug
Lead sponsor
Vyne Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
751 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
54
States / cities
Tucson, Arizona • Fremont, California • Los Angeles, California + 46 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2021 · Synced Oct 31, 2026, 5:27 AM EDT
Completed Phase 3 Interventional Results available

A Long-Term Safety Study of Tenapanor for the Treatment of IBS-C

NCT02727751
View directory record Official record
Conditions
Constipation Predominant Irritable Bowel Syndrome
Interventions
Tenapanor
Drug
Lead sponsor
Ardelyx
Industry
Eligibility
18 Years to 75 Years
Enrollment
312 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Sep 9, 2020 · Synced Oct 31, 2026, 5:27 AM EDT
Recruiting Not applicable Interventional

Community Health Advocates for Motivating PAP Use in Our Neighborhoods.

NCT06047353
View directory record Official record
Conditions
Obstructive Sleep Apnea
Interventions
Motivational Enhancement Therapy, Positive Airway Pressure (PAP) therapy
Behavioral · Device
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 100 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Dec 23, 2025 · Synced Oct 31, 2026, 5:27 AM EDT
Completed Phase 4 Interventional Results available

Clozapine for Cannabis Use in Schizophrenia

NCT01639872
View directory record Official record
Conditions
Schizophrenia, Cannabis Abuse, Cannabis Dependence, Dual Diagnosis
Interventions
Clozapine, Risperidone
Drug
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years to 55 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
9
States / cities
Garden Grove, California • Oakland, California • Miami, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated May 5, 2020 · Synced Oct 31, 2026, 5:27 AM EDT
Completed Phase 4 Interventional Results available

Long-acting Beta Agonist Step Down Study

NCT01437995
View directory record Official record
Conditions
Asthma
Interventions
Fluticasone/Salmeterol Diskus, Fluticasone Diskus
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
12 Years and older
Enrollment
459 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
19
States / cities
Tucson, Arizona • San Diego, California • Denver, Colorado + 15 more
Source: ClinicalTrials.gov public record
Updated Apr 25, 2017 · Synced Oct 31, 2026, 5:27 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Study of the Safety and Efficacy of APX3330 in Diabetic Retinopathy

NCT04692688
View directory record Official record
Conditions
Diabetic Retinopathy, Diabetic Macular Edema, NPDR - Non Proliferative Diabetic Retinopathy, PDR - Proliferative Diabetic Retinopathy
Interventions
APX3330, Placebo
Drug
Lead sponsor
Opus Genetics, Inc
Industry
Eligibility
18 Years and older
Enrollment
103 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
24
States / cities
Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 20 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2026 · Synced Oct 31, 2026, 5:27 AM EDT